Ketamine’s Secret Weapon: Why Some Patients Respond Better Than Others

Bottom line: Ketamine, whether used as a biomedical treatment or as part of psychedelic-assisted therapy, may work differently for different people — and the difference might lie in their history, not just their symptoms.

What if the real reason some people respond better to ketamine isn’t the drug itself — but the kind of depression they have, or the experiences they’ve had in life? A new study suggests that the past — specifically childhood trauma — might be the missing piece in understanding why ketamine works for some and not for others.

This is the question a new study is trying to answer: does ketamine work better for some people than others, and if so, why? The answer, it turns out, might be buried in the past — in the form of childhood trauma and the way depression is classified. It’s a story that doesn’t just change how we think about ketamine, but how we think about the very nature of depression itself.

The Two Faces of Ketamine: Medicine vs. Psychedelic

Ketamine is a drug that has gone from being a battlefield anesthetic to a potential miracle worker for treatment-resistant depression. But it has two faces — one that’s been rigorously studied in clinical trials, and another that’s often shrouded in mystery and myth.

In the biomedical model, ketamine is administered intravenously in a controlled medical setting. It’s a fast-acting antidepressant that can lift symptoms within hours, and it’s been shown to be effective in patients who haven’t responded to traditional antidepressants. But its effects are often short-lived, and the long-term benefits are still being explored.

The other face of ketamine is psychedelic-assisted therapy. Here, the drug is used in a different way — often in combination with psychotherapy, and sometimes with a guide or therapist present. The idea is that ketamine’s hallucinogenic properties can open the door to deep emotional processing, allowing patients to confront repressed memories or unresolved trauma. But this approach is still in its infancy, with limited scientific backing and a lot of anecdotal evidence.

The study in Australasian Psychiatry suggests that these two approaches may not be interchangeable. Instead, they might be better suited for different types of depression — and that the difference could be rooted in the way depression is classified.

Depression Subtypes and the Role of Trauma

The study builds on the work of Professor Gordon Parker, a leading figure in the field of mood disorders. Parker has long argued that depression is not a single condition, but a collection of subtypes with distinct biological and psychological underpinnings. One of his key contributions is the Sydney Melancholia Prototypic Index, a tool used to distinguish between melancholic and non-melancholic depression.

Melancholic depression is characterized by a deep sense of hopelessness, a lack of interest in anything, and a profound physical heaviness. It’s often linked with a history of trauma, particularly in childhood. Non-melancholic depression, on the other hand, is more about emotional pain, rumination, and a sense of worthlessness — and it may not be as closely tied to early trauma.

The study found that, in an open-label setting (where patients knew they were receiving ketamine), biomedical ketamine was more effective in patients with melancholic depression. This suggests that the drug may work best in cases where the depression is rooted in a deeper, more biologically driven pattern — perhaps one that is more amenable to pharmacological intervention.

But what about psychedelic-assisted therapy? The study notes that there are very few rigorous trials on the topic, and that the evidence is still sparse. One of the key limitations is that the psychedelic approach is often combined with psychotherapy, making it difficult to isolate the effects of the drug itself. This is a big hurdle — because if the therapy is the real driver of change, then it’s not clear whether the drug is the key factor at all.

The Hidden Power of Trauma: A Missing Link

One of the most intriguing findings of the study is the role of childhood trauma in shaping the response to ketamine. Patients who had a history of trauma — whether physical, emotional, or sexual — were more likely to benefit from biomedical ketamine, but only if their depression was classified as melancholic.

This raises a fascinating question: could trauma be a hidden factor in how ketamine works? If so, then the drug’s effectiveness might not be about its chemical properties, but about how it interacts with the brain’s stress response systems — systems that are often dysregulated in people with a history of trauma.

The study also points out that childhood trauma is often overlooked in the treatment of depression. While some clinicians may consider it, others may not, assuming that it’s a relic of the past. But if trauma is a key determinant of how ket, or any antidepressant, works, then it’s time to rethink how we approach treatment.

This idea is supported by a growing body of research that links early trauma with changes in the brain’s structure and function. For example, trauma can lead to a hyperactive amygdala — the brain’s fear center — and a hypoactive prefrontal cortex — the region responsible for rational thought. These changes may make some people more susceptible to depression, and also more responsive to certain treatments.

But again, the study is limited. It doesn’t provide a full picture of how trauma influences ketamine’s effects, and it doesn’t address whether psychedelic-assisted therapy might be more effective for non-melancholic depression — or for patients with a history of trauma.

Frequently Asked Questions

Q: Is ketamine a miracle drug for depression?
A: Ketamine is not a miracle drug, but it is a powerful tool in the treatment of treatment-resistant depression. Its effects are often rapid, but they are not guaranteed, and the long-term benefits are still being studied.

Q: Can psychedelic-assisted therapy be as effective as biomedical ketamine?
A: There is currently very little evidence to support this claim. Most studies on psychedelic-assisted therapy are small and lack rigorous design. More research is needed to determine whether it can be as effective as biomedical ketamine.

Q: Does childhood trauma affect how ketamine works?
A: The study suggests that childhood trauma may influence the effectiveness of ketamine, particularly in patients with melancholic depression. However, more research is needed to confirm this link.

Q: Why is depression classified into subtypes?
A: Depression is classified into subtypes to help clinicians understand the underlying biology and psychology of a patient’s condition. This can guide treatment decisions and improve outcomes.

Q: What’s the next step in researching ketamine and depression?
A: The next step is to conduct more rigorous, randomized controlled trials that compare different approaches to ketamine — including biomedical ketamine, psychedelic-assisted therapy, and integrated models. These studies should also explore the role of childhood trauma and other factors in shaping treatment outcomes.

Sources

• ¶Parker, G. (2026). Ketamine administered biomedically or as psychedelic-assisted therapy in treatment-resistant depression: Differing efficacy based on depressive subtype or presence of childhood trauma? Australasian Psychiatry, https://doi.org/10.1177/10398562261494440.

Educational Disclaimer

This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.

We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.

If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.

Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.